Catalent “has determined that it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 by the prescribed filing due date of February 9, 2024. The Company is working diligently and requires additional time to complete management’s continued evaluation of certain internal control matters and implementation of certain remediation efforts previously discussed in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023. The Company expects to file the Form 10-Q on or before the expiration of the five calendar day extension period provided in Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Based on currently available information and subject to the completion of the procedures described above, the Company does not expect any material change to the financial results to be included in the Form 10-Q compared to the financial information reported in the earnings release the Company furnished to the Securities and Exchange Commission on the Current Report on Form 8-K filed on February 9, 2024.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CTLT:
- Catalent reports Q2 EPS (24c), consensus (2c)
- Options Volatility and Implied Earnings Moves Today, February 09, 2024
- Catalent Inc (CTLT) Q2 Earnings Cheat Sheet
- Novo Nordisk price target raised to $135 from $115 at TD Cowen
- Catalent downgraded to Sector Perform from Outperform at RBC Capital
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue